1. Opening Hook
Indian pharma’s backbench kid just topped the class. While the biggies were blaming USFDA love letters and pricing pressure, Senores Pharma casually doubled profit and promised more. Their CEO sounded like a man who’d just reverse-engineered destiny — or at least, a few ANDAs.
From Ahmedabad to Arizona, the company’s playing 4D chess with ANDAs, CDMO contracts, and shiny US facilities. But wait till you hear how they plan to grow 100% profit this year and still call it “conservative.” Stick around — the prescriptions get stronger. 💊
2. At a Glance
- Revenue ₹162 crore (↑61% YoY) – CFO swears it’s “structural growth,” not caffeine.
- EBITDA ₹50 crore (↑113% YoY) – Margins hit 31%; efficiency so good it scares consultants.
- PAT ₹30 crore (↑131% YoY) – Profits doubled; accounting team finally smiling.
- Regulated Market Revenue ₹107 crore (↑87% YoY) – US plant printing dollars.
- Emerging Markets ₹32 crore (↑9% QoQ) – Still stretching before takeoff.
- Branded Generics ₹12 crore (↑10x YoY) – Doctors writing prescriptions faster than CFO can count.
- Operating Cash Flow ₹31 crore – Cash finally matching confidence.
3. Management’s Key Commentary
“We are confident of 50% revenue and 100% PAT growth in FY26.”
(Translation: CFO already booked a vacation to Goa.)
“Regulated markets grew 87% YoY; 8 new product launches this quarter.”
(Translation: We’re running out of shelves for all these ANDAs.)
“Our US capacity will rise from 1.2 to 2 billion units by FY27.”
(Translation: Because Americans really love our pills.)
“Branded generics in India grew 667% YoY.”
(Translation: Hospitals now remember our name — and our invoices. 😎)
“Cash flow improved 3x YoY.”
(Translation: We finally make money faster than we spend it on expansions.)
“CDMO segment now has 32 products; 50+ in pipeline.”
(Translation: We make drugs for others while quietly becoming a brand ourselves.)
“Emerging market margins to hit mid-teens in 2 years.”
(Translation: Patience, grasshopper — profits are
